4-(5-甲基-1,3,4-噁二唑-2-基)苯基硼酸 | 913835-70-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(5-甲基-1,3,4-噁二唑-2-基)苯基硼酸
• 中文别名: 4-(5-甲基-1,3,4-恶二唑-2-基)苯硼酸；4-(5-甲基-1,3,4-恶二唑-2-基)苯基硼酸
• 英文名称: (4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)boronic acid
• 英文别名: [4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]boronic acid
• CAS: 913835-70-8
• 化学式: C₉H₉BN₂O₃
• mdl: MFCD08436062
• 分子量: 203.993
• InChiKey: SPSKFVHUUJWUPB-UHFFFAOYSA-N

物化性质

• 熔点：
  188-190
• 沸点：
  418.2±55.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.68
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  79.4
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-(5-Methyl-1,3,4-oxadiazol-2-yl)phenylboronic acid
Product Name:
Synonyms: 2-(4-Boronophenyl)-5-methyl-1,3,4-oxadiazole

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-(5-Methyl-1,3,4-oxadiazol-2-yl)phenylboronic acid
Ingredient name:
CAS number: 913835-70-8

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H9BN2O3
Molecular weight: 204.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(5-甲基-1,3,4-噁二唑-2-基)苯基硼酸 、 3-溴-5-(吗啉-4-基)-7H-噻吩并[3,2-B]吡喃-7-酮 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 水 、 乙腈 为溶剂， 反应 3.0h， 以4%的产率得到3-[p-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]-5-morpholino-4-oxa-1-thia-7-indenone
  参考文献：
  名称：

  Thienopyranones as Kinase and Epigenetic Inhibitors

  摘要：

  这项发明涉及治疗疾病的方法，包括但不限于癌症、非癌性增生性疾病、败血症、自身免疫疾病、病毒感染、动脉粥样硬化、1型或2型糖尿病、肥胖症、炎症性疾病或Myc依赖性疾病，通过调节生物过程，通过抑制PI3激酶和/或溴结构域蛋白与构成给药的底物结合的生物过程，包括使用本文所定义的化合物的给药（或其药学上可接受的盐）的I-IX式。

  公开号：

  US20150344494A1

文献信息

• [EN] MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS<br/>[FR] DÉRIVÉS DE MANNOSE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：VERTEX PHARMA

  公开号：WO2013134415A1

  公开（公告）日：2013-09-12

  The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.

  本发明涉及用于治疗或预防细菌感染的化合物。这些化合物的公式为I：。发明还提供了包含这些化合物的药用可接受组合物，以及使用组合物治疗细菌感染的方法。最后，发明提供了制造本发明化合物的方法。
• [EN] SUBSTITUTED PYRAZOLE COMPOUNDS AND METHODS OF USING THEM FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES<br/>[FR] COMPOSÉS PYRAZOLE SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION POUR LE TRAITEMENT DE MALADIES HYPERPROLIFÉRATIVES
  申请人：BANTAM PHARMACEUTICAL LLC

  公开号：WO2018102453A1

  公开（公告）日：2018-06-07

  Disclosed are compounds useful, for example, in methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formulae (Ia), (Ib), (Ic), (Id) and (Ie), in which R1, L1, L2, Q, L3, R3, L4, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene.

  本文披露了一些化合物，例如在治疗高增殖性疾病如癌症的方法中有用，用于阻止癌细胞周期的方法，用于抑制癌细胞中谷胱甘肽合成的方法，以及用于药物中的相关化合物和用途。在某些实施例中，所述方法、用途和化合物参考了结构式(Ia)、(Ib)、(Ic)、(Id)和(Ie)的化合物，其中R1、L1、L2、Q、L3、R3、L4、R4、L5和R5如本文所述。在某些实施例中，本文披露的化合物对具有突变KRAS基因的癌症特别有效。
• [EN] HETEROCYCLIC COMPOUNDS AS EZH2 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE EZH2
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2015104677A1

  公开（公告）日：2015-07-16

  The present invention provides a compound of formula I, or an isotopic form, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, N-oxide or S-oxide thereof; and processes for their preparation. The invention further relates to pharmaceutical compositions containing the compounds and their use in the treatment of diseases or disorders mediated by EZH2 (enhancer of zeste homolog 2), particularly cancer.

  本发明提供了一种I式化合物，或其同位素形式、立体异构体、互变异构体、药学上可接受的盐、溶剂合物、多晶形态、前药、N-氧化物或S-氧化物；以及它们的制备方法。本发明还涉及含有这些化合物的药物组合物，并其在治疗由EZH2（增强子饰同源物2）介导的疾病或疾病中的用途，尤其是癌症。
• Structure–Activity Relationship Studies of Orally Active Antimalarial 3,5-Substituted 2-Aminopyridines
  作者：Diego González Cabrera、Frederic Douelle、Yassir Younis、Tzu-Shean Feng、Claire Le Manach、Aloysius T. Nchinda、Leslie J. Street、Christian Scheurer、Jolanda Kamber、Karen L. White、Oliver D. Montagnat、Eileen Ryan、Kasiram Katneni、K. Mohammed Zabiulla、Jayan T. Joseph、Sridevi Bashyam、David Waterson、Michael J. Witty、Susan A. Charman、Sergio Wittlin、Kelly Chibale

  DOI：10.1021/jm301476b

  日期：2012.12.27

  In an effort to address potential cardiotoxicity liabilities identified with earlier frontrunner compounds, a number of new 3,5-diaryl-2-aminopyridine derivatives were synthesized. Several compounds exhibited potent antiplasmodial activity against both the multidrug resistant (K1) and sensitive (NF54) strains in the low nanomolar range. Some compounds displayed a significant reduction in potency in

  为了解决由早期先驱化合物鉴定出的潜在心脏毒性问题，合成了许多新的3,5-二芳基-2-氨基吡啶衍生物。几种化合物对低纳摩尔范围内的耐多药（K1）和敏感（NF54）菌株均显示出有效的抗疟原虫活性。与先前报道的领先者类似物相比，某些化合物在hERG通道抑制试验中显示出显着的效力降低。这些新类似物中的几种在伯氏疟原虫小鼠模型中显示出有希望的体内功效，并将进一步评估为潜在的临床候选药物。描绘了体外抗血浆和hERG活性的SAR。
• MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20130261077A1

  公开（公告）日：2013-10-03

  The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.

  本发明涉及用于治疗或预防细菌感染的化合物。这些化合物的化学式为I：本发明还提供包含这些化合物的药学上可接受的组合物，并提供使用这些组合物治疗细菌感染的方法。最后，本发明提供了制备本发明化合物的方法。